Fortrea Expands Executive Team, Appoints New President of Clinical Pharmacology Services
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Should l Buy FTRE?
Fortrea announced it has expanded its executive team. Oren Cohen, MD who previously served as both Fortrea's chief medical officer, CMO, and president of Clinical Pharmacology Services, CPS, is now dedicated to his CMO responsibilities, namely medical strategy, scientific leadership, ethics and governance oversight across Fortrea's portfolio. Scott Dove, PhD joins Fortrea as its new president of Clinical Pharmacology Services, CPS, responsible for Fortrea's early clinical development solutions across its global network of clinical research units. Cohen and Dove both serve on Fortrea's Executive Committee.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FTRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FTRE
Wall Street analysts forecast FTRE stock price to rise
8 Analyst Rating
3 Buy
4 Hold
1 Sell
Hold
Current: 9.700
Low
7.00
Averages
15.33
High
25.00
Current: 9.700
Low
7.00
Averages
15.33
High
25.00
About FTRE
Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fortrea Holdings Under Investigation by Kahn Swick & Foti Amid Disappointing Financials
- Disappointing Financials: Fortrea Holdings reported that its Q4 and full-year 2024 results missed previously announced guidance for revenue and adjusted EBITDA, indicating lower-than-expected profitability post-spin-off, which could undermine shareholder confidence.
- Legal Action Risks: The company and its executives are facing a securities class action lawsuit for failing to disclose material information, which could lead to significant financial liabilities and exacerbate market concerns about its future prospects.
- Transition Services Agreements: Fortrea's agreements with Labcorp require payments for transitional services, and failure to effectively utilize these services may impose additional financial burdens, negatively impacting cash flow and operational efficiency.
- Investigation Focus: Kahn Swick & Foti is investigating whether Fortrea's executives breached their fiduciary duties to shareholders, and if violations are confirmed, it could lead to broader legal repercussions affecting the company's governance structure.
See More
Fortrea Updates J.P. Morgan Conference Presentation Time to January 13
- Conference Time Update: Fortrea announces an updated presentation time of 11:15 am PST on January 13, 2026, at the J.P. Morgan Annual Healthcare Conference, featuring CEO Anshul Thakral and CFO Jill McConnell, highlighting the company's leadership in clinical development.
- Investor Engagement: The conference will offer live streaming and replays accessible through the 'Events' section of Fortrea's Investor Relations website, enhancing communication and transparency with investors.
- Industry Position: As a leading global contract research organization, Fortrea provides clinical development solutions across over 20 therapeutic areas, showcasing its capability in driving healthcare innovation and accelerating therapies to patients.
- Global Reach: Operating in approximately 100 countries, Fortrea leverages three decades of experience and a robust investigator network to deliver agile solutions to clients, further solidifying its market position in the life sciences sector.
See More
VHT ETF Sees Notable Insider Buying in Fortrea and Biohaven Holdings
- Insider Buying Activity: Within the past six months, 16.2% of the holdings in the VHT ETF have seen insider buying, indicating increased market confidence which may positively influence investor decisions.
- Fortrea Holdings Update: Fortrea Holdings (FTRE), comprising 0.02% of the VHT ETF, has had 2 directors and officers purchase shares recently, suggesting internal confidence in the company's future, potentially attracting more investor interest.
- Biohaven Holdings Update: Biohaven Ltd (BHVN), also at 0.02% of the VHT ETF, has seen 4 directors and officers file Form 4s indicating purchases, reflecting optimism about its market prospects, which may enhance market interest in the stock.
- ETF Portfolio Insights: The total holdings of FTRE and BHVN in the VHT ETF are valued at $4,586,949 and $3,697,312 respectively, highlighting their relative significance in the healthcare sector and potentially impacting the overall performance of the ETF.
See More
Fortrea CEO Anshul Thakral to Present at J.P. Morgan Healthcare Conference
- Executive Participation: Fortrea CEO Anshul Thakral will participate in the J.P. Morgan Annual Healthcare Conference on January 13, 2025, enhancing company transparency and trust among investors through a presentation and Q&A session.
- Investor Relations Enhancement: CFO Jill McConnell and SVP of Investor Relations Tracy Krumme will also attend, aiming to improve investor understanding and confidence in Fortrea, which could stabilize the company's stock price.
- Industry Influence Showcase: As a leading global contract research organization, Fortrea's participation in such key conferences not only highlights its leadership in the life sciences sector but may also attract more potential clients and partners, fostering business growth.
- Clear Market Positioning: By showcasing Fortrea's clinical development solutions at the conference, the company is expected to further solidify its market position in the biopharmaceutical and medical device industries, driving future strategic development.
See More
Fortrea Holdings (FTRE) Price Target Raised by 18.02% to 13.36
Price Target Update: The average one-year price target for Fortrea Holdings (NasdaqGS:FTRE) has been revised to $13.36 per share, reflecting an 18.02% increase from the previous estimate of $11.32, although it represents a 24.68% decrease from the latest closing price of $17.74.
Fund Sentiment: There are currently 588 funds reporting positions in Fortrea Holdings, a decrease of 5.62% from the last quarter, with the average portfolio weight increasing to 0.04%. Total shares owned by institutions have decreased by 5.38% to 111,414K shares.
Shareholder Activity: Goldman Sachs Group increased its holdings in FTRE by 0.99% to 7,979K shares, while IJR - iShares Core S&P Small-Cap ETF decreased its holdings by 2.98% to 5,391K shares. Aqr Capital Management significantly reduced its stake by 74.41%.
Market Outlook: The put/call ratio for FTRE is 0.08, indicating a bullish sentiment among investors, suggesting optimism about the stock's future performance.
See More
Fortrea Holdings Stock Rises Following Barclays Upgrade
- Stock Performance: Fortrea Holdings (FTRE) shares experienced a slight increase of about 1% in recent trading on Monday.
- Analyst Upgrade: The rise in shares followed an upgrade from Barclays, indicating positive sentiment from analysts regarding the company's prospects.
See More
Fortrea Holdings Under Investigation by Kahn Swick & Foti Amid Disappointing Financials
- Disappointing Financials: Fortrea Holdings reported that its Q4 and full-year 2024 results missed previously announced guidance for revenue and adjusted EBITDA, indicating lower-than-expected profitability post-spin-off, which could undermine shareholder confidence.
- Legal Action Risks: The company and its executives are facing a securities class action lawsuit for failing to disclose material information, which could lead to significant financial liabilities and exacerbate market concerns about its future prospects.
- Transition Services Agreements: Fortrea's agreements with Labcorp require payments for transitional services, and failure to effectively utilize these services may impose additional financial burdens, negatively impacting cash flow and operational efficiency.
- Investigation Focus: Kahn Swick & Foti is investigating whether Fortrea's executives breached their fiduciary duties to shareholders, and if violations are confirmed, it could lead to broader legal repercussions affecting the company's governance structure.
See More
Fortrea Updates J.P. Morgan Conference Presentation Time to January 13
- Conference Time Update: Fortrea announces an updated presentation time of 11:15 am PST on January 13, 2026, at the J.P. Morgan Annual Healthcare Conference, featuring CEO Anshul Thakral and CFO Jill McConnell, highlighting the company's leadership in clinical development.
- Investor Engagement: The conference will offer live streaming and replays accessible through the 'Events' section of Fortrea's Investor Relations website, enhancing communication and transparency with investors.
- Industry Position: As a leading global contract research organization, Fortrea provides clinical development solutions across over 20 therapeutic areas, showcasing its capability in driving healthcare innovation and accelerating therapies to patients.
- Global Reach: Operating in approximately 100 countries, Fortrea leverages three decades of experience and a robust investigator network to deliver agile solutions to clients, further solidifying its market position in the life sciences sector.
See More
VHT ETF Sees Notable Insider Buying in Fortrea and Biohaven Holdings
- Insider Buying Activity: Within the past six months, 16.2% of the holdings in the VHT ETF have seen insider buying, indicating increased market confidence which may positively influence investor decisions.
- Fortrea Holdings Update: Fortrea Holdings (FTRE), comprising 0.02% of the VHT ETF, has had 2 directors and officers purchase shares recently, suggesting internal confidence in the company's future, potentially attracting more investor interest.
- Biohaven Holdings Update: Biohaven Ltd (BHVN), also at 0.02% of the VHT ETF, has seen 4 directors and officers file Form 4s indicating purchases, reflecting optimism about its market prospects, which may enhance market interest in the stock.
- ETF Portfolio Insights: The total holdings of FTRE and BHVN in the VHT ETF are valued at $4,586,949 and $3,697,312 respectively, highlighting their relative significance in the healthcare sector and potentially impacting the overall performance of the ETF.
See More
Fortrea CEO Anshul Thakral to Present at J.P. Morgan Healthcare Conference
- Executive Participation: Fortrea CEO Anshul Thakral will participate in the J.P. Morgan Annual Healthcare Conference on January 13, 2025, enhancing company transparency and trust among investors through a presentation and Q&A session.
- Investor Relations Enhancement: CFO Jill McConnell and SVP of Investor Relations Tracy Krumme will also attend, aiming to improve investor understanding and confidence in Fortrea, which could stabilize the company's stock price.
- Industry Influence Showcase: As a leading global contract research organization, Fortrea's participation in such key conferences not only highlights its leadership in the life sciences sector but may also attract more potential clients and partners, fostering business growth.
- Clear Market Positioning: By showcasing Fortrea's clinical development solutions at the conference, the company is expected to further solidify its market position in the biopharmaceutical and medical device industries, driving future strategic development.
See More
Fortrea Holdings (FTRE) Price Target Raised by 18.02% to 13.36
Price Target Update: The average one-year price target for Fortrea Holdings (NasdaqGS:FTRE) has been revised to $13.36 per share, reflecting an 18.02% increase from the previous estimate of $11.32, although it represents a 24.68% decrease from the latest closing price of $17.74.
Fund Sentiment: There are currently 588 funds reporting positions in Fortrea Holdings, a decrease of 5.62% from the last quarter, with the average portfolio weight increasing to 0.04%. Total shares owned by institutions have decreased by 5.38% to 111,414K shares.
Shareholder Activity: Goldman Sachs Group increased its holdings in FTRE by 0.99% to 7,979K shares, while IJR - iShares Core S&P Small-Cap ETF decreased its holdings by 2.98% to 5,391K shares. Aqr Capital Management significantly reduced its stake by 74.41%.
Market Outlook: The put/call ratio for FTRE is 0.08, indicating a bullish sentiment among investors, suggesting optimism about the stock's future performance.
See More
Fortrea Holdings Stock Rises Following Barclays Upgrade
- Stock Performance: Fortrea Holdings (FTRE) shares experienced a slight increase of about 1% in recent trading on Monday.
- Analyst Upgrade: The rise in shares followed an upgrade from Barclays, indicating positive sentiment from analysts regarding the company's prospects.
See More
